June 6, 2019 07:53 AM EDTUpdated June 24, 05:02 PM

The FDA is forcing a small antibiotic player back to the clinic for a new trial — 10 years after first rejection

Motif Bio $MTFB got a clear enough answer from the FDA on what regulators will need to see before they reconsider an OK on their …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The FDA is forc­ing a small an­tibi­ot­ic play­er back to the clin­ic for a new tri­al — 10 years af­ter first re­jec­tion